Nektar Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 3, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	1,906	172	108	425	2,493	3,050
Market Cap Growth	1058.47%	59.16%	-74.63%	-82.96%	-18.24%	-19.68%
Enterprise Value	1,803	129	-20	179	1,866	2,117
Last Close Price	68.11	13.95	8.47	33.90	202.65	255.00
PS Ratio	30.44	1.74	1.20	4.61	24.47	19.94
PB Ratio	15.73	2.82	0.82	1.16	3.67	2.83
P/TBV Ratio	22.40	2.82	0.82	1.46	4.14	3.05
EV/Sales Ratio	28.79	1.31	-	1.94	18.31	13.84
Debt / Equity Ratio	1.96	3.20	1.76	0.78	0.50	0.33
Net Debt / Equity Ratio	-1.21	-1.23	-0.76	-0.59	-0.68	-0.79
Net Debt / EBITDA Ratio	0.76	0.60	0.78	0.96	1.07	2.32
Net Debt / FCF Ratio	0.54	0.42	0.51	0.70	1.08	2.65
Asset Turnover	0.21	0.28	0.16	0.10	0.08	0.09
Inventory Turnover	-	-	1.91	1.24	1.60	1.39
Quick Ratio	4.09	4.18	5.97	7.53	8.90	9.55
Current Ratio	4.24	4.26	6.45	8.01	9.34	9.83
Return on Equity (ROE)	-180.24%	-124.10%	-110.95%	-70.39%	-59.64%	-35.80%
Return on Assets (ROA)	-27.98%	-23.14%	-15.25%	-16.43%	-21.00%	-13.51%
Return on Invested Capital (ROIC)	-	-450.92%	-131.09%	-111.04%	-137.22%	-81.99%
Return on Capital Employed (ROCE)	-58.00%	-53.60%	-39.00%	-37.40%	-43.20%	-26.70%
Earnings Yield	-6.34%	-69.35%	-256.12%	-86.68%	-21.01%	-14.57%
FCF Yield	-9.99%	-103.28%	-179.50%	-72.91%	-17.15%	-10.51%
Buyback Yield / Dilution	-14.07%	-8.24%	-1.53%	-2.10%	-2.64%	-2.05%

Updated Nov 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q